Pituitary Disorders Therapeutics
1. Mycapssa patent expiration
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide; Use of oral octreotide for long-term main...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11338011 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11141457 | CHIESI | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(14 years from now) | |
| US10695397 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US12251418 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US12246054 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US8535695 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US10238709 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11510963 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11857595 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11052126 | CHIESI | Method of treating diseases |
Feb, 2036
(10 years from now) | |
| US11890316 | CHIESI | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(14 years from now) | |
| US11986529 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US11969471 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US8329198 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US9265812 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| US9566246 | CHIESI | Pharmaceutical compositions and related methods of delivery |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 26, 2023 |
| Orphan Drug Exclusivity(ODE-474) | Jun 26, 2027 |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 26 June, 2020
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
MYCAPSSA family patents
2. Palsonify patent expiration
Treatment: Treatment of adults with acromegaly who have hepatic impairment and an inadequate response to surgery and/or for whom surgery is not an option; Treatment of adults with acromegaly who had an inadequat...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11414397 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10597377 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10351547 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US9896432 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| US10464918 | CRINETICS | NA |
Jan, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12208092 | CRINETICS | NA |
Mar, 2044
(18 years from now) | |
| US11957674 | CRINETICS | NA |
Sep, 2041
(15 years from now) | |
| US11266641 | CRINETICS | NA |
Sep, 2041
(15 years from now) | |
| US10875839 | CRINETICS | NA |
Jul, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2030 |
Drugs and Companies using PALTUSOTINE HYDROCHLORIDE ingredient
NCE-1 date: 25 September, 2029
Market Authorisation Date: 25 September, 2025
Dosage: TABLET
More Information on Dosage
PALSONIFY family patents
3. Signifor patent
expiration
Treatment: NA
Can you believe SIGNIFOR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8299209 | RECORDATI RARE | Pharmaceutical composition comprising cyclic somatostatin analogues |
Dec, 2025
(12 days ago) | |
| US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6225284 | RECORDATI RARE | Somatostatin peptides |
Jun, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 14, 2019 |
| Orphan Drug Exclusivity(ODE-34) | Dec 14, 2019 |
Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 14 December, 2012
Dosage: SOLUTION
More Information on Dosage
SIGNIFOR family patents
4. Somatuline Depot patent expiration
Treatment: Method of administering lanreotide acetate
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5595760 | IPSEN PHARMA | Sustained release of peptides from pharmaceutical compositions |
Mar, 2020
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2012 |
| New Dosing Schedule(D-131) | Mar 04, 2014 |
| Orphan Drug Exclusivity(ODE) | Aug 30, 2014 |
| New Indication(I-701) | Dec 19, 2017 |
| New Indication(I-754) | Sep 15, 2020 |
| Orphan Drug Exclusivity(ODE-82) | Dec 16, 2021 |
| Orphan Drug Exclusivity(ODE-156) | Sep 15, 2024 |
Drugs and Companies using LANREOTIDE ACETATE ingredient
NCE-1 date: 31 August, 2011
Market Authorisation Date: 30 August, 2007
Dosage: SOLUTION
More Information on Dosage
SOMATULINE DEPOT family patents